Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 457 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: SBRT Clear all

Conditions: Malignant Neoplasm, Brain, Brain Tumor
Interventions: Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Therapeutic Conventional Surgery; Other · Radiation · Procedure
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Resectable Pancreatic Cancer
Interventions: Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable, -Oxaliplatin 85 mg/m2 IV on Day 1, -Irinotecan 180 mg/m2 IV on Day 1, -5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours; Other · Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pancreatic Cancer
Interventions: Stereotactic Body Radiation Therapy, Preoperative Fractionated Radiation Therapy and Chemotherapy; Radiation
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: HepatoCellular Carcinoma, Unresectable HepatoCellular Carcinoma, Liver Cancer
Interventions: Stereotactic Body Radiation Therapy (SBRT), Sorafenib, Bavituximab; Radiation · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions: Nivolumab, Stereotactic Body Radiation Therapy (SBRT); Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more

Conditions: Hepatocellular Carcinoma
Interventions: Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy; Other · Radiation
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Lung Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Lung, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
Interventions: Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Radiology, Treatment Planning, Stereotactic Body Radiation Therapy, X-Ray Imaging; Procedure · Other · Radiation
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lung Cancer
Interventions: questionnaire administration, computed tomography, radiation therapy treatment planning/simulation; Other · Procedure · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hepatocellular Carcinoma
Interventions: SBRT, TACE; Radiation · Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Pancreas Cancer
Interventions: Biofeedback, Active Breathing Control Technique; Behavioral
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Liver Metastases, Lung Metastases, Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain
Interventions: ipilimumab, stereotactic radiosurgery, laboratory biomarker analysis; Biological · Radiation · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: Prostate stereotactic body radiotherapy with whole gland boost, Prostate stereotactic body radiotherapy with DIL boost; Radiation
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older · Male only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Adenocarcinoma, Prostate Cancer
Interventions: Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 1
States / cities: Lake Success, New York

Conditions: Spinal Metastases
Interventions: qMRI with Gadoteridol contrast agent; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Lung Neoplasms
Interventions: Sublobar Resection, Stereotactic Body Radiotherapy (SBRT); Procedure · Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Kidney Cancer
Interventions: conventional surgery, stereotactic radiosurgery; Procedure · Radiation
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Stage I Lung Cancer, Stage I Non-Small Cell Lung Cancer AJCC v7, Stage IA Non-Small Cell Lung Carcinoma AJCC v7, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Lung Cancer, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7
Interventions: Fludeoxyglucose F-18, Positron Emission Tomography (PET), Stereotactic Body Radiation Therapy (SBRT); Drug · Procedure · Radiation
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IV
Interventions: Durvalumab, Tremelimumab, Stereotactic Body Radiotherapy; Drug · Radiation
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Glioblastoma, WHO Grade II Glioma, WHO Grade III Glioma
Interventions: Intensity-Modulated Radiation Therapy, Quality-of-Life; Radiation · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cancer, Palliative Radiotherapy
Interventions: Lattice stereotactic body radiation therapy, Peripheral blood; Radiation · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Non-Small Cell Lung Cancer
Interventions: Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Placebo; Radiation · Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 42
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 39 more

Conditions: Locally Advanced Pancreatic Cancer, Borderline Pancreatic Inoperable Cancer, Pancreatic Cancer
Interventions: Folfirinox, Gemcitabine nab-Paclitaxel; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lung, Salivary Gland Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IVA Major Salivary Gland Cancer AJCC v8, Stage IVB Major Salivary Gland Cancer AJCC v8, Stage IVC Major Salivary Gland Cancer AJCC v8
Interventions: Nivolumab, Ipilimumab, Stereotactic Body Radiation Therapy; Biological · Radiation
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Child-Pugh Class A, Child-Pugh Class B, Recurrent Hepatocellular Carcinoma
Interventions: Stereotactic Body Radiation Therapy, Transarterial Chemoembolization, embolic agent, lipiodol; Radiation · Procedure · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Palo Alto, California

Search by objective public record fields.

Stereotactic Radiation Therapy Before Surgery for the Treatment of Resectable Brain Metastases

Borderline Pancreas Study: FOLFIRINOX +SBRT

Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer

Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study

Comfort Level of Two Abdominal Compression Methods Used to Hold Patients Still While Undergoing Stereotactic Body Radiation Therapy for Lung Tumors

Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma

Breath-Hold Technique for Pancreatic Stereotactic Body Radiation Therapy (SBRT) Patients

Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma

Whole Versus Partial Gland Boost During Prostate SBRT

SBRT for Organ Confined Prostate Cancer

Quantitative MRI for Functional Assessment Following SBRT for Spinal Metastases

Stereotactic Body Radiotherapy (SBRT) Versus Sublobar Resection for High-Risk Patients Non-Small Lung Cancer

Stereotactic Radiation Therapy in Treating Patients With Kidney Tumors

Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma

Palliative Lattice Stereotactic Body Radiotherapy (SBRT)

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer

Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers

Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization